

RESEARCH

Open Access



# Cancer morbidity and mortality trends in Trinidad and Tobago (2008–2018)

Chavin D. Gopaul<sup>1\*</sup>, Aruna Singh<sup>2</sup>, Akil Williams<sup>3</sup>, Dale Ventour<sup>4</sup> and Davlin Thomas<sup>5</sup>

## Abstract

**Purpose** Cancer is a leading cause of death in the Caribbean, and the Republic of Trinidad and Tobago is no exception. Evidence suggests that cancer incidence and mortality may vary based on demographic factors across the different cancer types. This study aimed to investigate the incidence and mortality trends associated with cancer cases in Trinidad and Tobago for the period 2008–2018, across different age groups, gender, and ethnicity.

**Methods** Data on 15,029 incident cancer cases were reported to the Dr. Elizabeth Quamina Cancer Registry between 2008 and 2018. The retrospective data were analyzed by sex, ancestry, and age, and were reported using Trinidad and Tobago population statistics for the period 2008–2018.

**Results** The incidence of prostate and breast cancers was high among males and females, respectively. Among males, the highest cancer mortality was associated with prostate, lung, colon, blood, and pancreatic cancers, respectively. Among females, the highest cancer mortality was associated with breast, ovary, colon, blood, and pancreatic cancers. The frequency of occurrence of the top five cancer sites was the highest among Afro-Trinidadians followed by Indo-Trinidadians. Most females diagnosed with breast cancer were at a localized stage, while most males diagnosed with breast cancer were at a distant or regional stage. Most individuals diagnosed with blood cancer were at a distant stage. For lung and colon cancer, the stage of diagnosis for most males and females was either distant or unknown. Majority of males are diagnosed with prostate cancer at an unknown stage.

**Conclusions** The findings indicate highest cancer incidence and mortality occur among Afro-Trinidadians. The stage at diagnosis varies across cancer types and gender.

**Keywords** Cancer trends, Cancer morbidity, Cancer mortality, Cancer incidence, Cancer registry, Trinidad and Tobago

\*Correspondence:

Chavin D. Gopaul  
[chavin.gopaul@gmail.com](mailto:chavin.gopaul@gmail.com)

<sup>1</sup> North Central Regional Health Authority, Ground Floor, Building 7, Eric Williams Medical Science Complex, Uriah Butler Highway, West Indies, Port of Spain, Trinidad and Tobago

<sup>2</sup> North West Regional Health Authority, Dundonald Street, West Indies, Port of Spain, Trinidad and Tobago

<sup>3</sup> Caribbean Centre for Health Systems Research and Development, University of the West Indies, St. Augustine, Trinidad and Tobago

<sup>4</sup> University of the West Indies, St. Augustine Campus, West Indies, St. Augustine, Trinidad and Tobago

<sup>5</sup> North Central Regional Health Authority, Third Floor, Building 39, Eric Williams Medical Science Complex, Uriah Butler Highway, West Indies, Port of Spain, Trinidad and Tobago

## Introduction

Cancer is considered the leading cause of death and is responsible for decreasing life expectancy globally [1, 2]. A report by the World Health Organisation (WHO) ranks cancer as the first or second cause of death among individuals aged 70 years or less among 112 countries [3]. The GLOBOCAN 2018 database, data compiled by the International Agency for Research on Cancer, suggested that there were about 18.1 million new cancer cases globally in 2018 [1]. The analysis also showed that the number of deaths from cancer in 2018 was 9.6 million [1]. Sung et al. [2], in their analysis of the GLOBOCAN database, noted that in the year 2020, there were an estimated 19.3 million new cases of cancer and 10 million deaths.



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

The increasing burden of cancer incidence and mortality is associated with social-economic development [2, 4]. Torre et al. argued that cancer incidence is expanding across countries of various income levels due to the growth and aging of the population [5] (Additional file 1).

Demographic factors such as gender have been suggested to influence the incidence and mortality associated with cancer [2]. According to Ferlay et al. [1], the type of cancer with highest incidence among males and females is lung cancer. Among males, prostate cancer is the most common [1, 2]. Females have a higher incidence of breast cancer [1, 2]. In men, lung cancer is associated with high mortality rates followed by liver cancer and stomach cancer [1]. Among females, the highest mortality is associated with breast cancer, followed by lung cancer, cervical cancer, and stomach cancer, respectively [1].

Cancer incidence and mortality rate are also associated with age. Chen et al. noted that the cancer incidence rate is lower among individuals aged 39 years and below [6]. The incidence of cancer is highest among individuals aged between 80 and 85 years [6]. According to Wang et al. [7], the incidence of liver cancer is 23.44 times and 27.28 times higher in males and females, respectively, aged 90–94 years compared to those aged 20–24 years. Concerning prostate cancer, Siegel et al. [8] noted that the highest incidence occurs among men aged 70–74 years.

Cancer is a leading cause of death in the Caribbean, and the Republic of Trinidad and Tobago is no exception [9]. The ancestral composition of the estimated 1.4 million population is diverse, with Trinidad's population comprised of 37.01% East Indian ancestry, 31.76% African ancestry, 23.52% Mixed ancestry, and <1% Chinese, White, and Syrian/Lebanese ancestry, and Tobago's population consisting of mostly African ancestry (85.29%) [10, 11]. The customs and traditions that the diverse ethnic composition brings with it are reflected in the socio-cultural landscape of the country [12]. Evidence suggests that cancer incidence and mortality may vary based on demographic factors across the different cancer types. Research on the epidemiology of cancer in Trinidad and Tobago as it relates to environmental, lifestyle, and demographic factors, including ancestry, is thus important in informing health programs and policies surrounding cancer. Understanding the incidence and mortality associated with cancer is important in the development of targeted interventions [5]. Previous research on cancer incidence and mortality in the country has been reported for the period 1995–2009 based on population data from the Dr. Elizabeth Quamina Cancer Registry, established as the National Cancer Registry of Trinidad and Tobago in 1994 [13]. There is therefore a need to update the existing literature concerning the cancer mortality and morbidity trends in the country. In this study, the objective

was to estimate the cancer incidence and mortality across different age groups, gender, and ethnicity, from 2008 to 2018, in Trinidad and Tobago.

## Methodology

The authors collected retrospective data from the National Cancer Registry of Trinidad and Tobago (NCRT&T) which is the national repository for all cancer data produced by the country. The dataset obtained from the NCRT&T contained age, sex, ethnicity, stage, grade, method of cancer detection and treatment, cancer site, date of incidence, age at diagnosis and cause of death. Cancer data produced by both public and private healthcare institutions are collected by the registry. Cancer histology is usually coded using WHO International Classification of Diseases of Oncology (ICD-O) code C61.9. Population estimates for the study were utilized from the Trinidad and Tobago Central Statistical Office (CSO) 2000 and 2018. CSO collects several population statistics that include but are not limited to ethnicity, sex and population rates disaggregated by year. The age standardized incidence and mortality rates (per 100,000 TT population) by age, sex, and individual years were calculated. Ethical approval was obtained from the North Central Regional Health Authority (NCRHA) Ethics Committee.

## Data analysis

IBM SPSS Statistics and Microsoft Excel were used for data analysis. Cross-tabulations were used to determine the number of cancer cases by year for the following variables: cancer sites, staging, gender, and ethnicity. The incidence and mortality rates were determined for the period 2008–2018. The incidence rate was determined by dividing the number of cancer cases each year by the mid-year population size for the corresponding year and multiplying the outcome by 100,000. The mortality rate was determined by dividing the number of deaths each year by the mid-year population size for the corresponding year and multiplying the outcome by 100,000.

## Results

### Incidence and mortality among males and females

The top three cancer sites with the highest incidence among men were prostate, lung, and colon for the period 2008–2018. In 2018, the incidence of prostate, lung, and colon cancers was 70.97, 23.90, and 13.49 per 100,000 males, respectively (Table 1).

The top three cancer sites with the highest mortality during the period 2008–2018 were prostate, lung, and colon. The mortality for prostate, lung, and colon cancers for 2018 was 22.00, 11.58, and 5.28 per 100,000 males, respectively (Table 2). Similar evidence was

**Table 1** Incidence by cancer site per 100,000 by years among men

Years	Cancer site								
	Anal	Blood	Breast	Lung	Colon	Pancreas	Prostate	Rectum	Stomach
2008	1.07	7.77	0.61	17.83	12.65	6.70	59.89	5.33	6.10
2009	0.46	7.31	1.22	20.40	11.72	7.91	57.68	4.72	5.02
2010	0.45	6.81	0.45	15.74	11.20	4.99	60.53	4.09	5.45
2011	0.75	6.45	0.60	16.81	11.11	4.80	51.63	4.20	4.50
2012	0.15	8.36	0.45	14.93	9.40	5.82	52.40	3.58	4.93
2013	0.30	7.29	1.19	17.40	7.58	5.50	45.35	2.08	3.72
2014	0.59	9.19	0.59	18.96	9.04	4.74	46.52	4.44	2.67
2015	0.89	11.22	0.89	20.53	11.67	7.24	56.12	3.54	3.69
2016	0.44	8.83	0.88	15.75	11.34	5.30	50.20	4.56	3.97
2017	0.44	9.84	1.03	21.89	9.26	6.91	59.65	3.67	3.23
2018	0.44	6.89	1.32	23.90	13.49	7.04	70.97	7.04	4.40

**Table 2** Mortality by cancer site men scale by rate per 100,000 by years

Years	Cancer site								
	Anal	Blood	Breast	Lung	Colon	Pancreas	Prostate	Rectum	Stomach
2008	0.15	4.57	0.00	13.10	5.18	5.18	26.21	2.29	4.57
2009	0.30	3.04	0.30	11.42	4.41	5.33	16.29	1.52	2.28
2010	0.15	2.12	0.15	9.53	4.99	2.57	16.95	1.21	2.72
2011	0.30	2.70	0.15	9.76	3.90	3.00	15.01	1.35	2.70
2012	0.15	3.58	0.15	8.06	2.99	3.58	18.66	1.04	1.79
2013	0.15	2.53	0.45	6.84	2.38	2.68	12.93	1.19	1.78
2014	0.30	2.67	0.00	10.22	2.96	2.52	12.00	1.04	0.89
2015	0.59	4.73	0.15	10.63	4.58	3.54	14.92	1.62	2.07
2016	0.29	2.94	0.29	6.77	4.71	2.50	12.51	1.18	1.91
2017	0.00	4.41	0.29	11.17	3.97	4.70	16.90	1.47	1.03
2018	0.15	2.64	0.29	11.58	5.28	3.96	22.00	2.20	2.64

found for the period 1995–2009, as the highest incidence and mortality rates were seen for prostate and lung cancers among men [5].

Breast, colon, and ovarian were the top three cancer sites among women with the highest incidence during the period 2008–2018. The incidence of breast, colon, and ovarian cancer in 2018 was 64.23, 12.55, and 11.96 per 100,000 females, respectively (Table 3).

The cancer sites associated with the highest mortality among females for the period 2008–2018 were breast, ovarian, and colon. Similarly, during the period 1995–2009, the highest incidence and mortality were observed for breast, cervical, and uterine cancer among women [5]. In 2018, the mortality for breast, ovarian, and colon cancers was 10.93, 5.02, and 4.58 per 100,000 females, respectively (Table 4).

#### Frequency distribution of cancer by ethnicity

The frequency distribution of the top five cancer sites (prostate, breast, colon, blood, and lung) by ethnicity were determined for the period 2008–2018. Concerning prostate cancer, Fig. 1 shows that the frequency of occurrence was the highest among Afro-Trinidadians between 2008 and 2018. Indo-Trinidadians had the second-highest frequency of prostate cancer. A similar trend was also observed for the remaining most frequently occurring cancer sites, with Afro-Trinidadians having the highest frequency followed by Indo-Trinidadians.

#### Percentage distribution of stage of cancer by sex

As shown in Table 5, most females (79.8%) and males (78.7%) with blood cancer had a distant stage distribution. The findings indicate that most persons (M: 41.7% &

**Table 3** Incidence by cancer site among women per 100,000 by years

Years	Cancer site								
	Anal	Blood	Breast	Lung	Colon	Ovary	Pancreas	Rectum	Stomach
2008	0.46	5.37	59.02	5.37	11.34	10.27	5.21	4.14	3.83
2009	0.61	5.82	58.34	6.58	9.80	8.88	4.90	3.52	4.29
2010	0.30	5.63	50.24	5.78	9.44	10.05	4.87	3.35	1.67
2011	0.60	7.25	55.61	7.25	11.64	10.43	4.99	3.17	3.93
2012	0.75	6.76	37.43	5.11	8.42	7.97	3.61	2.25	3.46
2013	0.60	6.14	34.43	4.79	8.98	7.04	4.34	1.80	3.14
2014	0.15	5.67	41.17	6.56	8.65	8.95	4.62	1.94	3.28
2015	0.45	8.18	50.26	7.29	11.60	9.37	5.65	3.42	3.27
2016	0.74	7.71	46.40	7.26	10.08	10.67	4.74	3.11	3.26
2017	0.44	6.07	53.85	6.81	9.17	12.28	5.62	2.37	2.51
2018	1.03	7.83	64.23	7.24	12.55	11.96	5.17	2.21	2.95

**Table 4** Mortality by cancer site women scale per 100,000 by years

Years	Cancer site								
	Anal	Blood	Breast	Lung	Colon	Ovary	Pancreas	Rectum	Stomach
2008	0.15	2.91	16.56	4.75	4.29	4.91	3.68	1.38	3.22
2009	0.31	2.14	14.70	3.52	4.44	3.06	2.30	1.07	2.14
2010	0.15	1.98	7.76	3.35	3.20	3.50	2.28	1.07	0.76
2011	0.15	2.27	11.94	3.02	3.78	3.78	2.57	0.91	1.96
2012	0.30	2.86	10.97	2.56	2.25	3.01	1.80	0.30	1.05
2013	0.00	2.10	9.28	1.80	4.34	1.95	2.69	0.75	1.35
2014	0.15	2.09	8.20	2.54	2.54	3.43	2.54	0.75	1.94
2015	0.00	3.12	10.26	3.72	5.06	4.16	3.12	0.89	1.49
2016	0.44	3.11	8.60	3.41	3.26	2.82	1.78	0.89	1.48
2017	0.00	2.22	13.17	3.40	3.11	4.73	3.70	0.44	1.33
2018	0.15	2.81	10.93	3.25	4.58	5.02	3.54	0.44	1.18

F: 43.7%) were diagnosed with a distant stage of lung cancer. For breast cancer, 30.3% of females were at a localized stage, 29.6% were at a regional stage, and 19.1% were at a distant stage. Among males with breast cancer, 30.2% were at a regional stage, 20.6% were at a distant stage, and 17.5% were at a localized stage. Most participants had an unknown stage of colon (M: 37.7% & F: 34.0%) and prostate (47.6%) cancer when diagnosed. Cancers are often diagnosed via metaphases, and during cancer registration, the site of the metaphases is not recorded. Hence, it is documented as an unknown site. It should be noted that cancer metastasized via the staging was recorded as distant.

## Discussion

### Incidence

Demographic factors such as gender have been suggested to influence the incidence of cancer [1, 2]. The findings of


this study indicate that the incidence of the major types of cancer by sex increased between 2008 and 2018. In this study, there was an increase in prostate, colon, and lung cancers among males for the period. Breast, lung, colon, blood, and ovarian cancers had increased among females for the same period. The study findings determined that prostate cancer has remained the leading cancer in males since 2008, which corroborates previous work [14]. Similar findings were observed by Yang et al. highlighting that the most common cancers among both sexes were colon and lung cancers [14].

It is evident from the outcome that the occurrence of major types of cancer varies across different ethnicities with the highest frequency of occurrence reported among Afro-Trinidadians followed by Indo-Trinidadians. The outcome of the study regarding the high incidence of major types of cancers among individuals from African backgrounds supports the previous

evidence [15]. Yedjou et al. [16] observed that breast cancer incidence is high among African-Americans. According to Taitt et al. [17], the incidence of prostate cancer is higher among individuals of African descent. DeSantis et al. [18] also reported that the incidence of lung cancer is high among African-Americans.

**Mortality**

The outcome indicates that among males and females the mortality due to major types of cancer such as prostate, lung, breast, and blood cancers declined during this period. Mortality due to breast and lung cancers also declined among females. The findings of this study



**Fig. 1** Occurrence of top five cancer sites across the different ethnicities




Fig. 1 continued

**Table 5** Cancer staging at the time of diagnosis between males and females

Sex	Stage	Blood, spleen (%)	Breast (%)	Bronchus, lung (%)	Colon (%)	Prostate (%)
Female	Distant	79.8	19.1	43.7	32.4	
	In situ	0.0	1.5	0.0	0.1	
	Localized	0.0	30.3	7.7	14.9	
	Regional	0.0	29.6	5.8	18.6	
	Unknown	20.2	19.5	42.8	34.0	
Male	Distant	78.7	20.6	41.7	28.4	22.1
	In situ	0.0	1.6	0.0	0.0	0.2
	Localized	0.3	17.5	5.1	15.8	22.7
	Regional	1.5	30.2	6.3	18.0	7.4
	Unknown	19.5	30.2	46.9	37.7	47.6

contradict the observations made by Azamjah et al. [19] which showed an increase in breast cancer mortality. However, Gomez et al. [20] reported observations similar to the study findings which showed a decline in breast cancer mortality among women. Siegel et al. [21] also

reported a decline in lung cancer mortality. The study findings suggest that colon cancer mortality increased slightly during 2008–2018 for both males and females. The findings also indicate that ovarian cancer mortality slightly increased during the period 2008–2018.

### Staging

Early diagnosis of cancer is important in the management and treatment [22]. Most females diagnosed with breast cancer are at a localized stage which suggests early diagnosis [23]. However, most males are diagnosed with breast cancer at either a distant or a regional stage, suggesting late diagnosis [23]. Most participants were diagnosed with a distant stage of blood cancer. The majority of staging diagnosis for colon and lung were either distant or unknown for both sexes. Late detection of those cancers can result in poorer prognosis and impact negatively on survival [24, 25]. The outcome therefore suggests that most participants are diagnosed late for leading cancers resulting in the cancer metastasizing in other sites of the body. However, most males are diagnosed with prostate cancer at an unknown stage when the information is not enough to figure out the stage or poor documentation techniques.

### Limitations

There are various limitations that should be taken into consideration in the study. The major limitation is the scope. The study did not assess how the incidence varies across the different age groups due to the lack of national data showing the population per age group. The ability of the findings to inform health policy efforts is limited by the failure to include other parameters such as diagnosis and screening and relating the parameters to the reported incidence and mortality rates.

### Conclusion

The study provides insights into cancer incidence and mortality from 2008 to 2018 in Trinidad and Tobago. The data provided in this study regarding the incidence and mortality of cancer could inform the actions taken by the healthcare providers and the relevant authorities to address public health concerns relating to cancer. Based on this study, there is a need to set healthcare policies to address the expected high incidence of prostate, lung, blood, colon, and pancreatic cancers among males. Steps should also be taken to address the expected high incidence of breast, blood, colon, ovarian, and lung cancers among females. The study outcome also highlights the need to focus on cancer occurrence among Afro-Trinidadians and Indo-Trinidadians. There is also a need to carry out early diagnosis to ensure early staging of breast cancer in males and blood cancer, colon cancer and lung cancer among males and females.

### Abbreviations

Afro-Trinidadian	Persons from Trinidad and Tobago who are of African Descent
Indo-Trinidadian	Persons from Trinidad and Tobago who are of Indian Descent
NCRT&T	National Cancer Registry of Trinidad and Tobago
Unknown site	Unknown origin or primary site

### Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s41043-023-00395-1>.

**Additional file 1:** SPSS outputs of cancer mortality in Trinidad and Tobago from 2008 to 2018.

### Acknowledgements

The authors would like to thank Ms Sacha Singh and Ms Saianna Solomon for the provision of technical support.

### Author contributions

CDG was responsible for the conception and design of the paper. CDG and AS were responsible for data collection, with intellectual contributions from AW. CDG and AS drafted the article. All authors contributed to the data analysis, interpretation of data, and critical revisions contributing to the intellectual content and approval of the final version of the manuscript.

### Funding

The authors have not received any funding or benefits from industry or elsewhere to conduct or publish this study.

### Availability of data and materials

The data that supports the findings of this study is available from the Trinidad and Tobago Cancer Registry and the TT Central Statistical Office upon request.

### Declarations

#### Ethics approval and consent to participate

The Trinidad and Tobago Cancer Registry provides deidentified data to investigators for research purposes. The authors therefore requested and obtained the deidentified cancer surveillance data used in this study from the registry. The Census data used is accessible to the public on the website of the Trinidad and Tobago Central Statistical Office. This study was approved by the North Central Regional Health Authority Ethics Committee and carried out in accordance with the North Central Regional Health Authority guidelines. Informed consent was waived by the North Central Regional Health Authority Ethics Committee as only deidentified data were used.

#### Consent for publication

Not applicable.

#### Competing interests

The authors declare that there is no conflict of interest regarding the publication of this article.

Received: 6 April 2022 Accepted: 31 May 2023

Published online: 27 June 2023

### References

1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *Int J Cancer*. 2019;144(8):1941–53.
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and

- mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2021;71(3):209–49.
3. World Health Organization (WHO). Global Health Estimates 2020: deaths by cause, age, sex, by country and by region, 2000–2019. WHO; 2020. Accessed 11 Dec 2020. <https://www.who.int/%20data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death>
  4. Wong MC, Lao XQ, Ho KF, Goggins WB, Shelly LA. Incidence and mortality of lung cancer: global trends and association with socioeconomic status. *Sci Rep.* 2017;7(1):1–9.
  5. Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global cancer in women: burden and trends. *Cancer Epidemiol Prev Biomarkers.* 2017;26(4):444–57.
  6. Chen W, Zheng R, Zhang S, Zeng H, Zuo T, Xia C, Yang Z, He J. Cancer incidence and mortality in China in 2013: an analysis based on urbanization level. *Chin J Cancer Res.* 2017;29(1):1.
  7. Wang F, Mubarik S, Zhang Y, Wang L, Wang Y, Yu C, Li H. Long-term trends of liver cancer incidence and mortality in China 1990–2017: a join-point and age–period–cohort analysis. *Int J Environ Res Public Health.* 2019;16(16):2878.
  8. Siegel DA, O’Neil ME, Richards TB, Dowling NF, Weir HK. Prostate cancer incidence and survival, by stage and race/ethnicity—United States, 2001–2017. *Morb Mortal Wkly Rep.* 2020;69(41):1473.
  9. Regional Health Observatory - Regional Mortality Information System. <https://www.paho.org/salud-en-las-americas-2017/?p=1457>. Accessed 15 Jan 2021.
  10. Central Statistical Office (Trinidad and Tobago). Trinidad & Tobago 2011 Housing and Population Census, vol. 2017. Trinidad: Ministry of Planning and Development; 2017.
  11. The Central Statistical Office. Trinidad and Tobago 2011 Population and Housing Census Demographic Report. Trinidad and Tobago. Trinidad and Tobago Ministry of Planning and Sustainable Development; 2012.
  12. Pan American Health Organization (PAHO). Health in the Americas, Book 636. Washington, DC: Pan American Health Organization; 2012.
  13. Warner WA, Lee TY, Badal K, Williams TM, Bajracharya S, Sundaram V, et al. Cancer incidence and mortality rates and trends in Trinidad and Tobago. *BMC Cancer.* 2018. <https://doi.org/10.1186/s12885-018-4625-x>.
  14. Yang R, Zhou Y, Wang Y, Du C, Wu Y. Trends in cancer incidence and mortality rates in the United States from 1975 to 2016. *Ann Transl Med.* 2020;8(24):1671–9.
  15. Newman LA, Kaljee LM. Health disparities and triple-negative breast cancer in African American women: a review. *JAMA Surg.* 2017;152(5):485–93.
  16. Yedjou CG, Sims JN, Miele L, Noubissi F, Lowe L, Fonseca DD, Alo RA, Payton M, Tchounwou PB. Health and racial disparity in breast cancer. In: Ahmad A, editor. *Breast cancer metastasis and drug resistance.* Cham: Springer International Publishing; 2019. p. 31–49.
  17. Taitt HE. Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. *Am J Mens Health.* 2018;12(6):1807–23.
  18. DeSantis CE, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Cancer statistics for African Americans, 2019. *CA Cancer J Clin.* 2019;69(3):211–33.
  19. Azamjah N, Soltan-Zadeh Y, Zayeri F. Global trend of breast cancer mortality rate: a 25-year study. *Asian Pac J Cancer Prev APJCP.* 2019;20(7):2015.
  20. Gomez SL, Von Behren J, McKinley M, Clarke CA, Shariff-Marco S, Cheng I, Reynolds P, Glaser SL. Breast cancer in Asian Americans in California, 1988–2013: increasing incidence trends and recent data on breast cancer subtypes. *Breast Cancer Res Treat.* 2017;164(1):139–47.
  21. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. *CA Cancer J Clin.* 2021;71(1):7–33.
  22. Koo MM, Swann R, McPhail S, Abel GA, Elliss-Brookes L, Rubin GP, Lyratzopoulos G. Presenting symptoms of cancer and stage at diagnosis: evidence from a cross-sectional, population-based study. *Lancet Oncol.* 2020;21(1):73–9.
  23. Islami F, Fedewa SA, Jemal A. Trends in cervical cancer incidence rates by age, race/ethnicity, histological subtype, and stage at diagnosis in the United States. *Prev Med.* 2019;123:316–23.
  24. Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, Mariotto AB, Lowy DR, Feuer EJ. The effect of advances in lung-cancer treatment on population mortality. *N Engl J Med.* 2020;383(7):640–9.
  25. Joachim C, Macni J, Drame M, Pomier A, Escarmant P, Veronique-Baudin J, Vinh-Hung V. Overall survival of colorectal cancer by stage at diagnosis: data from the Martinique Cancer Registry. *Medicine.* 2019;98(35):324–31.

## Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

